
Claims

1. Use of a compound in the manufacture of a medicament for treating, managing, or ameliorating a hematological cancer in a subject, wherein the compound comprises 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide, which has the following structure:



or a stereoisomer or mixture of stereoisomers, isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof , wherein the compound is to be administered to the subject in a dose of about 0.1 mg to about 20 mg, and wherein one or more of calcium, calcitriol, or vitamin D supplementation is to be further administered to the subject.

2. The use of claim 1, wherein the hematological cancer is acute myeloid leukemia.

3. The use of claim 2, wherein the acute myeloid leukemia is refractory or relapsed acute myeloid leukemia.

4. The use of claim 1, wherein the compound is to be administered on days 1 to 5 of a 28 day treatment cycle.

5. The use of claim 4, wherein the treatment cycle comprises a rest period of 23 days.

6. The use of claim 1, wherein the compound is to be administered on days 1 to 5 of a 42 day treatment cycle.

7. The use of claim 1, wherein the compound is to be administered on days 1 to 3 of a 28 day treatment cycle.

8. The use of claim 1, wherein the compound is to be administered on days 1 to 5 and days 15 to 19 of a 28 day treatment cycle.

9. The use of claim 4, wherein the treatment cycle is repeated at least once.

10. The use of claim 4, wherein the treatment cycle is repeated 2 to 4 times.

11. The use of claim 1, wherein the compound is to be administered in a dose of about 0.1 mg to about 10 mg.

12. The use of claim 1, wherein the compound is to be administered in a dose from about 0.3 mg to about 8.1 mg.

13. The use of claim 1, wherein the compound is to be administered in a dose of about 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 3.6 mg, 5.4 mg or 8.1 mg.

14. The use of claim 1, wherein the compound is to be administered in a dose of about 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3.6 mg.

15. The use of claim 1, wherein one or more of calcium, calcitriol, or vitamin D supplementation is to be administered to the subject prior to administration of the compound.

16. The use of claim 1, wherein one or more of calcium, calcitriol, or vitamin D supplementation is to be administered to the subject at least 3 days prior to administration of the compound on day 1 of the cycle.

17. The use of claim 1, wherein the subject does not have a disorder disrupting normal calcium homeostasis or preventing calcium supplementation.

18. The use of claim 1, wherein the compound is in a polymorph form for administration to the subject.

19. The use of claim 1, wherein the compound is in an amorphous form for administration to the subject. .

20. The use of claim 1, wherein the medicament is a lyophilized formulation, wherein the lyophilized formulation comprises the compound, a buffer and a bulking agent.

21. The use of claim 1, wherein a therapeutically effective amount of a second active agent or a supportive care therapy is to be further administered to the subject.

22. The use of claim 1, wherein the subject is a patient 18 years or older.

23. The use of claim 1, wherein the hematological cancer is myelodysplastic syndrome.

24. The use of claim 23, wherein the myelodysplastic syndrome is refractory or relapsed myelodysplastic syndrome.

25. The use of claim 23, wherein the compound is to be administered on days 1 to 5 of a 28 day treatment cycle.

26. The use of claim 23, wherein the compound is to be administered on days 1 to 5 of a 42 day treatment cycle.

27. The use of claim 23, wherein the compound is to be administered on days 1 to 3 of a 28 day treatment cycle.

28. The use of claim 23, wherein the compound is to be administered on days 1 to 5 and days 15 to 19 of a 28 day treatment cycle.

29. The use of claim 25, wherein the treatment cycle is repeated at least once.

30. The use of claim 25, wherein the treatment cycle is repeated 2 to 4 times.

31. The use of claim 23, wherein the compound is to be administered in a dose of about 0.1 mg to about 10 mg.

32. The use of claim 23, wherein the compound is to be administered in a dose from about 0.3 mg to about 8.1 mg.

33. The use of claim 23, wherein the compound is to be administered in a dose of about 0.3 mg, 0.6 mg, 1.2 mg, 2.4 mg, 3.6 mg, 5.4 mg or 8.1 mg.

34. The use of claim 23, wherein the compound is to be administered in a dose of about 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3.6 mg.

35. The use of claim 23, wherein one or more of calcium, calcitriol, or vitamin D supplementation is to be administered to the subject.

36. The use of claim 35, wherein one or more of calcium, calcitriol, or vitamin D supplementation is to be administered to the subject prior to administration ofthe compound.

37. The use of claim 35, wherein one or more of calcium, calcitriol, or vitamin D supplementation is to be administered to the subject at least 3 days prior to administration of the compound on day 1 of the cycle.

38. The use of claim 23, wherein the subject does not have a disorder disrupting normal calcium homeostasis or preventing calcium supplementation.

39. The use of claim 23, wherein the compound is in a polymorph form for administration to the subject.

40. The use of claim 23, wherein the compound is in an amorphous form for administration to the subject.

41. The use of claim 23, wherein the medicament is a lyophilized formulation for administration to the subject, wherein the lyophilized formulation comprises the compound, a buffer and a bulking agent.

42. The use of claim 23, wherein a therapeutically effective amount of a second active agent or a supportive care therapy is to be further administered to the subject.

43. The use of claim 23, wherein the subject is a patient 18 years or older.